Annual report pursuant to Section 13 and 15(d)

NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details)

v3.7.0.1
NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details)
 12 Months Ended
Aug. 01, 2015
USD ($)
shares
Oct. 01, 2014
USD ($)
May 31, 2017
USD ($)
May 31, 2016
USD ($)
shares
Feb. 28, 2017
USD ($)
Jul. 20, 2016
USD ($)
Feb. 29, 2016
ft²
a
NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]              
Allocated Share-based Compensation Expense     $ 0 $ 327,500      
Chief Executive Officer [Member]              
NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]              
Employment Agreement, Term   5 years          
Officers' Compensation   $ 150,000   150,000      
Deferred Compensation Arrangement with Individual, Description   performance bonus equal to 2% of CLS Labs’ annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary)          
Share-based Compensation Arrangement by Share-based Payment Award, Description   annual stock options, exercisable at the fair market value of CLS Labs’ common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million          
Due to Officers or Stockholders, Current     37,500 $ 250,000      
Chief Executive Officer [Member] | Convertible Notes Payable [Member]              
NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]              
Debt Instrument, Face Amount         $ 112,500 $ 250,000  
Chief Operating Officer [Member]              
NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]              
Employment Agreement, Term 5 years            
Officers' Compensation $ 150,000            
Deferred Compensation Arrangement with Individual, Description performance bonus equal to 2% of the Company’s annual EBITDA, up to a maximum annual cash compensation of $1 million (including his base salary)            
Share-based Compensation Arrangement by Share-based Payment Award, Description annual stock options, exercisable at the fair market value of the Company’s common stock on the date of grant, in an amount equal to 2% of its annual EBITDA up to $42.5 million and 4% of its annual EBITDA in excess of $42.5 million            
Chief Operating Officer [Member] | One Time Signing Bonus [Member]              
NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares) | shares 250,000     250,000      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 1 year     1 year      
Former Officer [Member]              
NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]              
Due to Officers or Stockholders, Current       $ 16,290      
Building [Member] | Affiliated Entity [Member]              
NOTE 13 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]              
Area of Real Estate Property (in Square Feet) | ft²             42,392
Area of Land (in Acres) | a             1.92
Operating Leases, Rent Expense     $ 177,844 $ 177,844